Trial Profile
Pilot Therapy Using Betaine in Combination With Peginterferon Alpha-2a Plus Ribavirin in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Pegylated Interferon and Ribavirin
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Betaine (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 08 Aug 2011 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Apr 2009 New trial record